Fasting

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Jeudi, mars 7, 2024

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

L-Nutra Unveils Groundbreaking Research on Fasting Mimicking Diets (FMDs) and Reduced Biological Age Score

Retrieved on: 
Mercredi, février 28, 2024

LOS ANGELES, Feb. 28, 2024 /PRNewswire/ -- L-Nutra Inc., a leading nutrition technology company developing evidence-based Nutrition for Longevity and Nutrition as Medicine programs, is excited to announce the release of a groundbreaking longevity and healthy aging study published in Nature Communications, a prestigious Nature portfolio journal. The data suggests that following three consecutive monthly rounds of ProLon® 5-Day may decrease a person's biological age score by 2.5 years. 

Key Points: 
  • The data suggests that following three consecutive monthly rounds of ProLon® 5-Day may decrease a person's biological age score by 2.5 years.
  • L-Nutra's flagship product, ProLon® 5-day Fasting Mimicking Diet (FMD), the first patented precision nutrition program shown to support cellular rejuvenation and metabolic reset effects of prolonged fasting, was provided to participants.
  • This research further solidifies L-Nutra's commitment to advancing scientific understanding and practical applications of nutrition for living longer and healthier.
  • This study marks a significant step forward in understanding the effect of fasting-mimicking diets (FMD) in cellular rejuvenation, metabolic reset, and supporting healthy living.

Healthy Foods Deliver Defense Against Cancer and Heart Disease

Retrieved on: 
Mercredi, février 21, 2024

The vitamins and minerals in "good-for-you" nourishment provide energy for daily living, help the body grow and repair and can prevent diet-related illnesses like cancer and heart disease.

Key Points: 
  • The vitamins and minerals in "good-for-you" nourishment provide energy for daily living, help the body grow and repair and can prevent diet-related illnesses like cancer and heart disease.
  • According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death in the United States, followed by cancer.
  • There are a number of factors that can increase the risk of developing heart disease, including high blood pressure, high cholesterol, obesity and diabetes .
  • Research shows that in addition to inhibiting colon, prostate and breast cancer cell growth, they can also protect against heart disease.

Affordability and Gut Health Predicted as Leading Food Purchase Drivers in 2024

Retrieved on: 
Jeudi, février 15, 2024

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- In the ever-evolving food and nutrition space, affordability and gut health are positioned to take center stage as leading drivers of consumer purchasing decisions in 2024. These insights come from the annual Today's Dietitian and Pollock Communications "What's Trending in Nutrition" survey of 564 Registered Dietitian Nutritionists (RDNs), offering a glimpse into the shifting landscape of what we eat and why as consumers increasingly prioritize both their well-being and their wallets.

Key Points: 
  • NEW YORK, Feb. 15, 2024 /PRNewswire/ -- In the ever-evolving food and nutrition space, affordability and gut health are positioned to take center stage as leading drivers of consumer purchasing decisions in 2024.
  • Call It a Gut Feeling: Gut Health Climbs the List While Affordability & Convenience Maintain Top Spots as Consumer Purchase Drivers
    As consumers navigate recent increases in grocery prices, RDNs predict that affordability will be an important driver of consumer purchases.
  • Research into the benefits of a healthy microbiome, from mood to weight management has sparked interest in foods that support gut health.
  • The COVID-19 pandemic demonstrated a need to regularly protect immune health, and consumers continue to shop for foods that support immunity.

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Retrieved on: 
Jeudi, février 15, 2024

Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.

Key Points: 
  • Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.
  • The multi-center study evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes.
  • “We are excited to reach this milestone in exploring the potential of Afrezza for a younger generation living with diabetes,” said Dr. Kevin Kaiserman, Senior Vice President, Clinical Development and Medical Affairs for MannKind Corporation.
  • “We expect to complete a primary endpoint analysis in the fourth quarter.”
    More information on the study details is available at: https://www.clinicaltrials.gov/study/NCT04974528

‘Tarry awhile’: how the Black spiritual tradition of waiting expectantly could enrich your approach to Lent

Retrieved on: 
Mardi, février 13, 2024

For the 40 days between Ash Wednesday and Easter Sunday, observers devote themselves to fasting, prayer and acts of generous giving.

Key Points: 
  • For the 40 days between Ash Wednesday and Easter Sunday, observers devote themselves to fasting, prayer and acts of generous giving.
  • Entitled Tarry Awhile: Wisdom from Black Spirituality for People of Faith, this selection speaks to the growing salience of Black spirituality globally, especially in regards to Christianity.
  • The Archbishop’s Lenten book choice cordially redirects religious literary attention to the influence of Black spirituality in Anglican thought.
  • “To tarry” is to linger in anticipation – be that of a person or an occurrence.
  • In a Christian context, it is about waiting on God, expectantly.

Tarrying in the Christian tradition

  • Overwhelmed with sorrow to the point of death, he asks his disciples to, “tarry here and watch with me”.
  • In biblical literature, tarrying refers to an individual or community patiently, longingly waiting in one setting or state for something.
  • The concept of tarrying surfaces in the historical development of academic Christian theology.
  • In Black Christian spirituality, the concept of tarrying exists as a familiar, mature spiritual ritual that practically manifests in a variety of ways.
  • Like meditating, tarrying prioritises mindfulness over negligence or indifference.
  • Within the Pentecostal tradition, specifically, tarrying is seen as a spiritual discipline.
  • Religiously, tarrying means replacing the attention seeking anxieties of everyday life with a focus on the spiritual, the social and the relational.


Dr Christopher Wadibia receives funding from a postdoctoral research fellowship specialising in race, theology, and religious studies based at Pembroke College, University of Oxford.

L-Nutra Unveils Groundbreaking Study on Fasting Mimicking Diets (FMDs) and Chronic Lymphocytic Leukemia

Retrieved on: 
Mardi, février 13, 2024

CLL is the most prevalent form of leukemia in Western countries, and this groundbreaking research suggests a promising avenue for more effective treatment options.

Key Points: 
  • CLL is the most prevalent form of leukemia in Western countries, and this groundbreaking research suggests a promising avenue for more effective treatment options.
  • The study focused on the synergistic effects of cyclic fasting combined with proteasome inhibitors, experimental medication showing early promise for the treatment of CLL.
  • This suggests a potential benefit of fasting mimicking diets (FMDs) in treatment of milder CLL cases even without additional interventions.
  • The findings from this study open up potential new possibilities for CLL treatment strategies and food as medicine in general.

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Retrieved on: 
Mardi, février 6, 2024

“These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.

Key Points: 
  • “These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.
  • “We believe that preserving lean muscle mass through our highly selective approach to myostatin inhibition in combination with GLP-1 RA therapy has the potential to transform the management of weight loss.
  • In parallel, Scholar Rock is developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity.
  • SRK-439 also improved fat mass loss (–36.60% to –46.32% from baseline with semaglutide; –17.31% to –19.04% from baseline with liraglutide).

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Retrieved on: 
Jeudi, février 1, 2024

CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of this year.

Key Points: 
  • The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of this year.
  • "Clearance of the IND for DA-1726 allows us to proceed with the Phase 1 program for this novel GLP-1 and glucagon dual receptor, a potential new treatment to address the significant obesity market," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo.
  • Secondary endpoints include the PK of DA-1726, assessed via serum concentrations over time and metabolite profiling at the highest doses of DA-1726.
  • Exploratory endpoints will include the effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI), among others.

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

Retrieved on: 
Lundi, janvier 29, 2024

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonist

Key Points: 
  • Gross proceeds from the PIPE are expected to be $50.25 million, before deducting any placement agent fees and offering-related expenses.
  • The PIPE financing is expected to close on January 31, 2024, subject to the satisfaction of customary closing conditions.
  • The PIPE financing was co-led by a life sciences-focused investor and 5AM Ventures, with participation from Ally Bridge Group, Sphera Healthcare, Altium Capital, Driehaus Capital Management and other institutional investors.
  • Piper Sandler is acting as the lead placement agent and Oppenheimer & Co. is acting as a placement agent for the PIPE financing.